BioPharmSignal logoBioPharmSignal

Biotech News

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos Therapeutics (ALGS)Aligos TherapeuticsPartnership

Aligos to receive an upfront payment of $25M USD Up to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties Amoytop to fund its development program in Greater China Amoytop is a leading Chinese pharmaceutical company with commercially approved

Open original release

Related news

ALGSAligos Therapeutics2026-04-14 20:05 EST

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

MLYSMineralys Therapeutics2026-06-03 10:00 EST

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

ALGSAligos Therapeutics2026-05-13 06:05 EST

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

MNKDMannKind2026-05-06 10:30 EST

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

PMCBPharmaCyte Biotech2025-09-02 13:20 EST

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

VANIVivani Medical2026-07-07 11:35 EST

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

MLYSMineralys Therapeutics2026-05-30 15:15 EST

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

VANIVivani Medical2026-06-25 11:30 EST

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

VKTXViking Therapeutics2026-07-22 20:05 EST

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

View all latest news

Aligos Therapeutics

Aligos Therapeutics is a biotechnology company focused on liver disease, virology, and cardiometabolic targets. Its pipeline is centered on difficult diseases with a need for differentiated small-molecule science.

Recent company news

ALGSAligos Therapeutics2026-05-27 06:30 EST

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

ALGSAligos Therapeutics2026-05-13 06:05 EST

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

ALGSAligos Therapeutics2026-05-07 20:06 EST

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

ALGSAligos Therapeutics2026-04-30 20:05 EST

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

ALGSAligos Therapeutics2026-04-24 12:00 EST

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
4.08 USD
Market cap
32.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States